Lepu Medical Technology (Beijing) Co., Ltd. (300003.SZ) Latest Company News

Oct 23, 2026, 08:22 UTC
Lepu Medical reported first-three-quarter revenue of 4.627 billion yuan, down 6.32% year over year, and net profit of 678 million yuan, down 30.93%.
Source:
- finance.sina.cn
Oct 23, 2026, 08:22 UTC
Lepu Medical reported third-quarter revenue of 1.413 billion yuan, down 9.99% year over year, and net profit of 179 million yuan, down 38.58%.
Source:
- finance.sina.cn
- finance.sina.cn
Oct 15, 2026, 08:12 UTC
Among active small- and mid-cap Hong Kong shares, GDS Holdings Ltd fell 15.7% to HK$24.52, COSCO Shipping Energy Transportation fell 15.6% to HK$18.34, Laekna fell 15.3% to HK$18.62, Tianchen Biotech fell 14.4% to HK$72.40, Yangtze Optical Fibre and Cable fell 13.2% to HK$122.60, 160 HEALTH fell 11.9% to HK$2.485, Shanghai Biren Technology Co., Ltd. fell 11.9% to HK$24.98, Tsugami China fell 11.7% to HK$38.60, Montage Technology Group Ltd. fell 11.1% to HK$202, Lenovo Holdings fell 11.0% to HK$17.64, Impro Precision Industries Ltd. fell 10.6% to HK$5.855.
Source:
- aastocks.com
Oct 8, 2026, 02:23 UTC
Leshin Co. and other shareholders established Shenzhen Jingzhao Intelligent Computing Technology Co., whose business scope includes AI software and systems, AI hardware, and integrated-circuit products.
Source:
- finance.sina.cn
Oct 3, 2026, 12:30 UTC
Lepu Medical confirmed its interventional multi-channel brain-computer interface product completed preclinical animal testing and advanced into human investigator-initiated clinical trials.
Source:
- chinatechnews.com
Sep 23, 2026, 12:03 UTC
Lepu Medical's application for Class II medical device registration certificates for its upper-arm electronic blood pressure monitors was accepted by the Guangdong Provincial Medical Products Administration.
Source:
- finance.sina.cn
Sep 10, 2026, 00:18 UTC
Lifetech Scientific's subsidiary Shenzhen Jianxin Medical Technology and Fuwai Hospital received official notice from China's National Medical Products Administration that their Lantval aortic valve replacement system entered the special review procedure for innovative medical devices on September 9, 2026, marking the company's eighteenth product to enter this procedure.
Source:
- finance.sina.cn
- aastocks.com
Aug 28, 2026, 04:23 UTC
Lifetech Scientific reported a net loss of RMB 34.348 million for the six months ended June 2026, compared with a net profit of RMB 55.074 million a year earlier, with revenue down 11.2% year-on-year to RMB 601 million.
Source:
- aastocks.com
Aug 24, 2026, 08:24 UTC
Pu Zhongjie, actual controller and chairman of Lepu Medical, increased his stake in the company by 853,700 shares on August 24, 2026, representing 0.046% of total share capital, at an average price of 11.71 yuan per share.
Source:
- finance.sina.cn
Aug 21, 2026, 10:35 UTC
Lepu Medical director Wang Qihong resigned due to retirement, and Sun Lei was nominated to replace him as a non-independent director.
Source:
- finance.sina.cn
Aug 21, 2026, 10:34 UTC
Lepu Medical announced the transfer of its 54.2384% stake in Shanghai Minwei Biotechnology to its subsidiary Xintai Medical for 1.088 billion yuan, making Xintai Medical the controlling shareholder.
Source:
- finance.sina.cn
- aastocks.com
Aug 21, 2026, 10:33 UTC
Lepu Medical announced its 2026 first-half results: net profit attributable to shareholders was 499 million yuan, down 27.71% year-on-year; revenue was 3.214 billion yuan, down 4.61% year-on-year.
Source:
- finance.sina.cn
Aug 21, 2026, 10:33 UTC
Lepu Medical announced an interim cash dividend of 1.63 yuan per 10 shares (tax inclusive), based on 1.843 billion shares, with a total cash dividend of approximately 300 million yuan (tax inclusive).
Source:
- finance.sina.cn
Aug 17, 2026, 11:07 UTC
Lepu Medical's subsidiary Shanghai Minwei Biotechnology received approval from China's National Medical Products Administration to conduct clinical trials for its MWN117 injection, targeting overweight or obesity indications.
Source:
- finance.sina.cn
Aug 13, 2026, 08:55 UTC
Lepu Medical's shareholder 725 Institute plans to issue exchangeable bonds of up to 600 million yuan, backed by its shares in Lepu Medical.
Source:
- finance.sina.cn
Jul 2, 2026, 07:42 UTC
Lepu Medical's controlling shareholder Pu Zhongjie pledged 11.93 million shares on June 30 to secure debt repayment, and released 27.93 million shares from pledge on July 1.
Source:
- finance.sina.cn

300003.SZ

Lepu Medical reported first-three-quarter revenue of 4.627 billion yuan, down 6.32% year over year, and net profit of 678 million yuan, down 30.93%.

Lepu Medical reported third-quarter revenue of 1.413 billion yuan, down 9.99% year over year, and net profit of 179 million yuan, down 38.58%.

Leshin Co. and other shareholders established Shenzhen Jingzhao Intelligent Computing Technology Co., whose business scope includes AI software and systems, AI hardware, and integrated-circuit products.

Lepu Medical confirmed its interventional multi-channel brain-computer interface product completed preclinical animal testing and advanced into human investigator-initiated clinical trials.

Lepu Medical's application for Class II medical device registration certificates for its upper-arm electronic blood pressure monitors was accepted by the Guangdong Provincial Medical Products Administration.

Lifetech Scientific reported a net loss of RMB 34.348 million for the six months ended June 2026, compared with a net profit of RMB 55.074 million a year earlier, with revenue down 11.2% year-on-year to RMB 601 million.

Pu Zhongjie, actual controller and chairman of Lepu Medical, increased his stake in the company by 853,700 shares on August 24, 2026, representing 0.046% of total share capital, at an average price of 11.71 yuan per share.

Lepu Medical director Wang Qihong resigned due to retirement, and Sun Lei was nominated to replace him as a non-independent director.

Lepu Medical announced the transfer of its 54.2384% stake in Shanghai Minwei Biotechnology to its subsidiary Xintai Medical for 1.088 billion yuan, making Xintai Medical the controlling shareholder.

Lepu Medical announced its 2026 first-half results: net profit attributable to shareholders was 499 million yuan, down 27.71% year-on-year; revenue was 3.214 billion yuan, down 4.61% year-on-year.

Lepu Medical announced an interim cash dividend of 1.63 yuan per 10 shares (tax inclusive), based on 1.843 billion shares, with a total cash dividend of approximately 300 million yuan (tax inclusive).

Lepu Medical's subsidiary Shanghai Minwei Biotechnology received approval from China's National Medical Products Administration to conduct clinical trials for its MWN117 injection, targeting overweight or obesity indications.

Lepu Medical's shareholder 725 Institute plans to issue exchangeable bonds of up to 600 million yuan, backed by its shares in Lepu Medical.

Lepu Medical's controlling shareholder Pu Zhongjie pledged 11.93 million shares on June 30 to secure debt repayment, and released 27.93 million shares from pledge on July 1.